Mesa Laboratories, Inc. (NASDAQ: MLAB) is a Healthcare company (Medical - Specialties) with a market capitalization of $757M. The Maz Rating grades it against the other companies in its sector.
Mesa Laboratories, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $134.60, Mesa Laboratories, Inc. trades at 113.5x trailing earnings, 3.0x sales and 3.9x book value, with an EV/EBITDA of 18.7. Over the last twelve months it generated about $253M of revenue and $7M of net income. It runs a gross margin of 66.6%, an operating margin of 10.4% and a net margin of 2.7%. It shows return on equity of 3.5%, return on invested capital of 3.6% and a free cash flow yield of 6.5%. On the balance sheet: a debt-to-equity ratio of 0.42 and a current ratio of 1.90. Over the past 52 weeks the share price ranged from $69.51 to $144.35, with a beta of 1.08.
Mesa Laboratories, Inc. pays a dividend yielding 0.48%, with 53% of earnings paid out. Its Maz Dividend Score is 2.70 out of 5, ranked against the other dividend payers in its sector (Safety 4.23, Growth 1.23, Yield 2.37, Consistency 2.59).
8 Wall Street analyst ratings cover the stock: 3 Buy and 5 Hold, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.